FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e827-e834
DOI: 10.1093/cid/ciac433 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 10.06.2022. Verfasst von Frederique J Vink und 17 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pathology, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: MicroRNAs, Papillomavirus Infections, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union Horizon, 2020.
Abstract (Originalsprache)
Background
High-grade squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN) grade 2/3 lesions in human papillomavirus (HPV)–positive women <30 years of age have high spontaneous regression rates. To reduce overtreatment, biomarkers are needed to delineate advanced CIN lesions that require treatment. We analyzed the FAM19A4/miR124-2 methylation test and HPV16/18 genotyping in HPV-positive women aged <30 years, aiming to identify CIN2/3 lesions in need of treatment.
Methods
A European multicenter retrospective study was designed evaluating the FAM19A4/miR124-2 methylation test and HPV16/18 genotyping in cervical scrapes of 1061 HPV-positive women aged 15–29 years (690 ≤CIN1, 166 CIN2, and 205 CIN3+). A subset of 62 CIN2 and 103 CIN3 were immunohistochemically characterized by HPV E4 expression, a marker for a productive HPV infection, and p16ink4a and Ki-67, markers indicative for a transforming infection. CIN2/3 lesions with low HPV E4 expression and high p16ink4a/Ki-67 expression were considered as nonproductive, transforming CIN, compatible with advanced CIN2/3 lesions in need of treatment.
Results
FAM19A4/miR124-2 methylation positivity increased significantly with CIN grade and age groups (<25, 25–29, and ≥30 years), while HPV16/18 positivity was comparable across age groups. FAM19A4/miR124-2 methylation positivity was HPV type independent. Methylation-positive CIN2/3 lesions had higher p16ink4a/Ki-67-immunoscores (P = .003) and expressed less HPV E4 (P = .033) compared with methylation-negative CIN2/3 lesions. These differences in HPV E4 and p16ink4a/Ki-67 expression were not found between HPV16/18–positive and non-16/18 HPV–positive lesions.
Conclusions
Compared with HPV16/18 genotyping, the FAM19A4/miR124-2 methylation test detects nonproductive, transforming CIN2/3 lesions with high specificity in women aged <30 years, providing clinicians supportive information about the need for treatment of CIN2/3 in young HPV-positive women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pathology, Amsterdam, the Netherlands.
- Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
- Self-screen B.V., Amsterdam, The Netherlands.
- Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, the Netherlands.
- Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark.
- Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, Scotland.
ORCID-Profile: Frederique J Vink, Chris J L M Meijer, Albertus T Hesselink, Arno N Floore, Birgit I Lissenberg-Witte, Jesper H Bonde, Kate Cuschieri, Ramya Bhatia, Mario Poljak, Anja Oštrbenk Valenčak, Peter Hillemanns, Marta Del Pino, Gemma G Kenter, Renske D M Steenbergen, Daniëlle A M Heideman, Maaike C G Bleeker
Förderung
- European Union Horizon
- 2020
Zitieren
APA
Vink, F. J., Meijer, C. J. L. M., Hesselink, A. T., Floore, A. N., Lissenberg-Witte, B. I., Bonde, J. H., Pedersen, H., Cuschieri, K., Bhatia, R., Poljak, M., Oštrbenk Valenčak, A., Hillemanns, P., Quint, W. G. V., Del Pino, M., Kenter, G. G., Steenbergen, R. D. M., Heideman, D. A. M., & Bleeker, M. C. G. (2023). FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. Clinical Infectious Diseases, 76(3), e827-e834. https://doi.org/10.1093/cid/ciac433
Vancouver
Vink FJ, Meijer CJLM, Hesselink AT, Floore AN, Lissenberg-Witte BI, Bonde JH, et al. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. Clinical Infectious Diseases. 2023;76(3):e827-e834. doi:10.1093/cid/ciac433
BibTeX
@article{Vink2023,
author = {Vink, Frederique J and Meijer, Chris J L M and Hesselink, Albertus T and Floore, Arno N and Lissenberg-Witte, Birgit I and Bonde, Jesper H and Pedersen, Helle and Cuschieri, Kate and Bhatia, Ramya and Poljak, Mario and Oštrbenk Valenčak, Anja and Hillemanns, Peter and Quint, Wim G V and Del Pino, Marta and Kenter, Gemma G and Steenbergen, Renske D M and Heideman, Daniëlle A M and Bleeker, Maaike C G},
title = {FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e827--e834},
doi = {10.1093/cid/ciac433}
}
EUVIMED